Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases AS Rifaioglu, H Atas, MJ Martin, R Cetin-Atalay, V Atalay, T Doğan Briefings in bioinformatics 20 (5), 1878-1912, 2019 | 448 | 2019 |
Learning functional properties of proteins with language models S Unsal, H Atas, M Albayrak, K Turhan, AC Acar, T Doğan Nature Machine Intelligence 4 (3), 227-245, 2022 | 116 | 2022 |
Crowdsourced mapping of unexplored target space of kinase inhibitors A Cichońska, B Ravikumar, RJ Allaway, F Wan, S Park, O Isayev, S Li, ... Nature communications 12 (1), 3307, 2021 | 68 | 2021 |
CROssBAR: comprehensive resource of biomedical relations with knowledge graph representations T Doğan, H Atas, V Joshi, A Atakan, AS Rifaioglu, E Nalbat, A Nightingale, ... Nucleic acids research 49 (16), e96-e96, 2021 | 26 | 2021 |
How to approach machine learning-based prediction of drug/compound–target interactions H Atas Guvenilir, T Doğan Journal of Cheminformatics 15 (1), 16, 2023 | 17 | 2023 |
Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line İZ Durusu, HH Hüsnügil, H Ataş, A Biber, S Gerekçi, EA Güleç, C Özen Leukemia Research 55, 33-40, 2017 | 17 | 2017 |
Protein domain-based prediction of drug/compound–target interactions and experimental validation on LIM kinases T Doğan, E Akhan Güzelcan, M Baumann, A Koyas, H Atas, IR Baxendale, ... PLoS Computational Biology 17 (11), e1009171, 2021 | 15 | 2021 |
Martin, MJ—Cetin-Atalay, R.—Atalay, V.—Dogan, T.: Recent Applications of Deep Learning and Machine Intelligence on in silico Drug Discovery: Methods, Tools and Databases AS Rifaioglu, H Atas Briefings in Bioinformatics 20 (5), 1878-1912, 2019 | 9 | 2019 |
Evaluation of methods for protein representation learning: a quantitative analysis S Unsal, H Ataş, M Albayrak, K Turhan, AC Acar, T Doğan bioRxiv, 2020.10. 28.359828, 2020 | 7 | 2020 |
Phylogenetic and other conservation-based approaches to predict protein functional sites H Atas, N Tuncbag, T Doğan Computational Drug Discovery and Design, 51-69, 2018 | 6 | 2018 |
CROssBAR: comprehensive resource of biomedical relations with deep learning applications and knowledge graph representations T Doğan, H Atas, V Joshi, A Atakan, AS Rifaioglu, E Nalbat, A Nightingale, ... bioRxiv, 2020.09. 14.296889, 2020 | 3 | 2020 |
CROssBAR: comprehensive resource of biomedical relations with network representations and deep learning V Joshi, T Doğan, R Atalay, MJ Martin, R Saidi, H Zellner, V Volynkin, ... | 2 | 2019 |
Anti-Cancer Effects of Clofazimine As a Single Agent and in Combination with Cisplatin in Multiple Myeloma I Durusu, HH Husnugil, H Atas, A Biber, S Gerekci, AE Gulec, C Ozen Blood, The Journal of the American Society of Hematology 128 (22), 5897-5897, 2016 | 2 | 2016 |
Target Specific De Novo Design of Drug Candidate Molecules with Graph Transformer-based Generative Adversarial Networks A Ünlü, E Çevrim, A Sarıgün, H Çelikbilek, HA Güvenilir, A Koyaş, ... arXiv preprint arXiv:2302.07868, 2023 | | 2023 |
Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools R Cetin-Atalay, DC Kahraman, E Nalbat, AS Rifaioglu, A Atakan, ... Journal of Gastrointestinal Cancer 52 (4), 1266-1276, 2021 | | 2021 |
Repurposing of antipsychotic agent trifluoperazine for multiple myeloma treatment: in vitro studies H Ataş Middle East Technical University, 2016 | | 2016 |
CROssBAR: Comprehensive Resource of Biomedical Relations with Network Representations and Deep Learning”, Oral presentation M Atalay, T Doğan, R Atalay, E Nalbat, A Rifaioğlu, H Ataş, M Martin | | |